Webinar
World View 2024 - An international summit on Newborn Screening
Streamed live across the world during June 2024, Newborn Screening World View gathered together international thought leaders in newborn screening, providing the whole newborn screening community a unique chance to Learn, Share and Develop.
The 3 day agenda focused on Activating Newborn Screening Around the World, Redefining Newborn Screening Practices and The Future Shape of Newborn Screening. With over 1100 participants online and 90 countries represented, this page provides the opportunity to watch the presentations on demand over the entire 3 days.
Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations please consult your local health care professionals.
To view the full content please answer a few questions
Day 1 - Activating newborn screening
Greetings from international society for neonatal screening - Jim Bonham, UK
WHO progress on maternal and newborn health globally - Anshu Banerjee, WHO, Switzerland
MLD family journey "Nala & Teddi" - Ally Wallace, UK
Convince governments to act - Carmencita Padilla, Philippines
Partnerships & advocacy to address the sickle cell funding paradox - Hon. Jane Ruth Aceng, Minister of Health, Uganda
Leveraging the HIV DBS infrastructure for NBS in Uganda - Charles Kiyaga, Uganda
Unitaid: Saving lives through health innovation - Kelsey Barrett, Switzerland
Round table - How to accelerate access of newborn health innovations in LMICs - Hon. Jane Ruth Aceng (MOH), Anshu Banerjee (WHO), Carmencita Padilla, Kelsey Barrett (UNITAID), Jim Bonham (ISNS)
Day 2 - Redefining newborn screening practices
Improving the lab efficiencies
Effective and efficient newborn screening for X-linked adrenoleukodystrophy: one extraction with two injections - Mei Baker, USA
Tennessee's progress in implementing steroid profiling for congenital adrenal hyperplasia - Lauren Tyler, USA
Transitioning from lab developed tests to NeoBase™ 2 - Sarah Smith, UK
Software integration workflow improvements in the NBS laboratory - Brendan Reilly, USA
Q&A session - Improving the lab efficiencies
New disorders in consideration
Newborn screening for MLD: Methodology and results of pilot studies across 4 countries - Mike Gelb, USA
MLD: A treatable disease, the perspective of a neuropediatrician - Francesca Fumagalli, Italy
Michigan's experience adding guanidinoacetate and creatine for GAMT deficiency to the NeoBase™ 2 assay - Krystyna Weiss-Pawlak, USA
Implementation of MPS II testing in a high throughput newborn screening laboratory - Patricia Ryland, USA
Q&A session - New disorders in consideration
Day 3 - The future shape of newborn screening
World programs expanding the menu to SCID, SMA, and LSDs
Building tomorrow: The professional journey of an SMA scientist in the newborn screening era - Vanessa Romanelli, Brazil
Implementation of the Eonis™ Q system for newborn screening for severe combined immunodeficiency and spinal muscular atrophy in Catalonia - Ana Argudo-Ramirez, Spain
Thailand government national mandate: Expanding to cover IEMs and SMA - Khunton Wichajarn, Thailand
National implementation of LSD NBS in Korea - Sung-Eun Cho, Korea
Q&A session - World programs- expanding the menu to SCID, SMA, and LSDs
Next potential expansion candidates on molecular NBS
The case for universal CMV screening: How Minnesota became the first state in the USA to screen all newborns for congenital CMV infection - Mark Schleiss, USA
One year of universal screening for cytomegalovirus in Minnesota - Carrie Wolf, USA
Toward prospective newborn screening for angelman, prader-willi and DUP 15q syndromes; validation of a DNA methylation-based test - Kate Kucera, USA
Q&A session - Next potential expansion candidates on molecular NBS
NBS genomics
Newborn screening using whole genome sequencing: The generation study - David Bick, UK
Experience from a United States statewide newborn sequencing study: Early check - Holly Peay, USA
Improving screening performance with 2nd tier NGS - Expanding newborn screening towards genomics - Asbjørg Stray-Pedersen, Norway
Considerations of ethics and equity when using genomics in newborns - Amy Gaviglio, USA
Round table: NBS genomics - David Bick, Holly Peay, Asbjørg Stray-Pederson, Amy Gaviglio